Relevant bibliographies by topics / Ioflupano

Academic literature on the topic 'Ioflupano'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ioflupano.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ioflupano"

1

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez, and C. Durán Herrera. "Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento." Revista Española de Medicina Nuclear 28, no. 1 (February 2009): 2–5. http://dx.doi.org/10.1016/s0212-6982(09)70207-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Díaz Platas, Lucía, Stefan Prado Wohlwend, Mónica Romero Otero, Alba Iniesta Medel, and Luis Ramudo Cela. "Relación entre la pureza radioquímica del 123i-ioflupano y la captación extracraneal (tiroidea y parotídea)." Ars Pharmaceutica (Internet) 56, no. 4 (December 2015): 225–30. http://dx.doi.org/10.4321/s2340-98942015000400006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Puñal Riobóo, J., L. Varela Lema, A. Serena Puig, and A. Ruano-Ravina. "Efectividad del 123I-ioflupano (DaTSCAN©) en el diagnóstico de síndromes parkinsonianos. Una revisión sistemática." Revista Española de Medicina Nuclear 26, no. 6 (December 2007): 375–84. http://dx.doi.org/10.1157/13112366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Durán Ferreras, Eduardo, and Andrés Durán Ferreras. "Utilidad de la SPECT con 123I-ioflupano (DaT-scan) en el parkinsonismo inducido por fármacos." Revista de Neurología 52, no. 06 (2011): 382. http://dx.doi.org/10.33588/rn.5206.2010757.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

García Vicente, A. M., J. Vaamonde Cano, A. Soriano Castrejón, C. Martínez Delgado, P. Talavera Rubio, V. M. Poblete García, S. Ruiz Solís, S. Rodado Marina, and M. Cortés Romera. "SPECT con ioflupano I-123 en la catalogación de pacientes con síndrome parkinsoniano y vasculopatía cerebral." Revista Española de Medicina Nuclear 24, no. 6 (December 2005): 392–403. http://dx.doi.org/10.1016/s0212-6982(05)74184-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez, and C. Durán Herrera. "Valor predictivo negativo de la SPECT con ioflupano-I-123 en los trastornos del movimiento (réplica)." Revista Española de Medicina Nuclear 28, no. 5 (September 2009): 267–68. http://dx.doi.org/10.1016/j.remn.2009.05.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

García-Gómez, F. J., D. García-Solís, F. J. Luis-Simón, V. A. Marín-Oyaga, F. Carrillo, P. Mir, and R. J. Vázquez-Albertino. "Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano." Revista Española de Medicina Nuclear e Imagen Molecular 32, no. 6 (November 2013): 350–56. http://dx.doi.org/10.1016/j.remn.2013.02.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

García Vicente, A. M., J. Vaamonde Cano, V. M. Poblete García, S. Rodado Marina, M. Cortés Romera, S. Ruiz Solís, R. Ibáñez Alonso, and A. Soriano Castrejón. "Utilidad de la imagen de transportadores de dopamina (SPECT cerebral con ioflupano I-123) en la valoración de los trastornos del movimiento." Revista Española de Medicina Nuclear 23, no. 4 (January 2004): 245–52. http://dx.doi.org/10.1016/s0212-6982(04)72294-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Soriano Castrejón, Angel, Ana María García Vicente, Montserrat Cortés Romera, Julia Vaamonde Cano, Sonia Rodado Marina, Victor Manuel Poblete García, Sebastián Ruiz Solís, and María del Prado Talavera Rubio. "123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders." Brazilian Archives of Biology and Technology 48, spe2 (October 2005): 115–26. http://dx.doi.org/10.1590/s1516-89132005000700017.

Full text
Abstract:
123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra.
APA, Harvard, Vancouver, ISO, and other styles
10

Antonini, Angelo, and Giorgio L. Colombo. "Il ruolo della SPECT in associazione a iofupane nella diagnosi della Malattia di Parkinson: i risultati di un’esperienza." Farmeconomia. Health economics and therapeutic pathways 3, no. 3 (September 15, 2002): 125–33. http://dx.doi.org/10.7175/fe.v3i3.750.

Full text
Abstract:
According to the latest data, in Italy 200.000 patients are affected by the Parkinson’s Disease, and the trend is bound to go up. Generally the diagnosis, crucial in this pathology, is based on the clinic observation. But the absence of typical signs or symptoms increases the possibility of diagnostic mistakes. Ioflupane (DATSCAN ®) is a new diagnostic agent indicated for detecting loss of functional dopaminergic neuron terminals in the striatum of patients with clinically uncertain Parkinsonian Syndromes. The use of Ioflupane (DATSCAN ®) in association with the single-photon emission computed tomography (SPECT) allows to improve the diagnosis. Applying systematically this diagnostic model could cause a significant reduction in hospedalization cost, with less trouble for patients and a better quality of life. Aim of this study is to show the clinical and economic consequences of the use of Ioflupane (DATSCAN â) in association with SPECT as a new standard for the diagnosis of Parkinson’s Disease, considering the perspective of the National Heath System (NHS) and a single hospital structure.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ioflupano"

1

GELOSA, GIORGIO. "Correlati di neuroimaging funzionale dell'aprassia nelle demenze neurodegenerative." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2013. http://hdl.handle.net/10281/49886.

Full text
Abstract:
Aim. High order control of movements and gestures is attributed to a cortico-subcortical network involving the fronto-parietal cortex and connections, and the striatum. Damage within the basal ganglia would be neither necessary nor sufficient to cause clinically evident apraxia, but would add to praxis errors caused by fronto-parietal dysfunction. While the cortical component of the praxis network has been repeatedly investigated, this is the first study directly exploring the contribution of the striatum: we correlated dopaminergic uptake measured with 123-ioflupane Single Photon Emission Tomography (SPET) and PET FDG cerebral metabolism with severity of ideomotor apraxia in Cortico-Basal Syndrome (CBS). Patients and methods. Patients were evaluated with De Renzi’s Test for Ideomotor Apraxia, which allows to score separately movements performed with hand and fingers or with arm and hand, and meaningful and meaningless gestures. Both upper limbs were assessed. Occipital-striatum ratios of dopaminergic uptake were measured semiquantitatively for left and right caudate and putamen. Partial correlation analysis between apraxia scores and SPET parameters was conducted using Unified Parkinson’s Disease Rating Scale III, MMSE scores, disease duration and age as covariates. Bonferroni correction for multiple comparisons was applied. PET FDG uptake was quantified using SPM software. Results. Eleven patients diagnosed with CBS according to recent standardised criteria were included into the study. They were eight women and three men with a mean age of 70.3 years +7.8, a mean disease duration of 28.2 months +14.6, and a MMSE score of 19.7 +4.1 on average. Partial correlation analysis after Bonferroni correction showed a statistically significant relationship between reduced dopaminergic uptake in the left striatum (caudate and putamen) and poor performance of gestures with the left fingers. A correlation was demonstrated between a cluster of reduced metabolism at PET FDG in the frontal left hemisphere and right apraxia scores in the CBS subjects. Discussion. Even if confirmation in a larger sample is needed, our findings confirm a cortical involvement in the praxis network and support a role of the basal ganglia on praxis dysfunction in subjects with CBS. Conclusions. In CBS, damage to the basal ganglia is not only responsible for extrapyramidal signs and symptoms, but also contributes to the development of ideomotor apraxia.
APA, Harvard, Vancouver, ISO, and other styles
2

Grilo, Afonso Silvestre. "Aplicações do iodo em diagnóstico e terapêutica." Master's thesis, 2015. http://hdl.handle.net/10451/27001.

Full text
Abstract:
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2015
O Iodo, situado no grupo 17 e no período 5 da tabela periódica é um elemento químico não-metálico essencial à vida, assumindo um papel vital no crescimento e desenvolvimento do organismo. Ao longo deste trabalho o iodo será descrito enquanto elemento químico, dando especial atenção aos vários isótopos de iodo, principalmente àqueles que possuem aplicações terapêuticas e de diagnóstico no âmbito da Medicina Nuclear. Assim, no decurso desta revisão bibliográfica abordar-se-á as características físicas e químicas do Iodo, enquanto elemento químico, e dos seguintes isótopos: 123I, 124I, 125I e 131I. Para além disto, serão ainda referidos os seus métodos de obtenção, e as suas propriedades nucleares que tornam possível a sua aplicação a nível médico. Neste contexto abordar-se-ão pormenorizadamente os radiofármacos de iodo utilizados em diagnóstico, nomeadamente: para estudos da glândula da tiroide (NaI-[131I]), para diagnóstico da Doença Isquémica Cerebral (iofetamina-[123I]) e ainda para diagnóstico da doença de Parkinson (Ioflupano-[123I]). Para além destes, serão ainda abordados outros radiofármacos de iodo que são aplicados a nível terapêutico, tais como: o NaI-[131I] (hipertiroidismo e carcinoma da tiroide), as sementes de 125I (cancro da próstata), o Tositumomab-[131I] (linfoma folicular não-Hodgkin) e o anticorpo monoclonal anti-tenascina 81C6 marcado com 131I (glioma). Por último, será ainda abordada a possível aplicação de nanopartículas marcadas com radioisótopos de iodo no âmbito da Medicina Nuclear.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Ioflupano"

1

Blokdijk, G. J. Ioflupane I-123; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Ioflupano"

1

Azzopardi, Vanessa, Matthew Guy, and Emma Lewis. "Identifying Shape-Based Biomarkers for Diagnosis of Parkinson’s Disease from Ioflupane (123I) SPECT Data." In Communications in Computer and Information Science, 94–105. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95921-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brahim, A., J. M. Górriz, J. Ramírez, and L. Khedher. "Intensity Normalization of 123 I-ioflupane-SPECT Brain Images Using a Model-Based Multivariate Linear Regression Approach." In Artificial Computation in Biology and Medicine, 68–77. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18914-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ioflupano"

1

Krol, Andrzej, Mary A. McGrath, Brian T. Carey, and David H. Feiglin. "Comparative studies of collimator performance in DaTscan (Ioflupane I-123) striatal SPECT." In SPIE Medical Imaging, edited by John B. Weaver and Robert C. Molthen. SPIE, 2013. http://dx.doi.org/10.1117/12.2007027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Castillo-Barnes, D., D. Salas-Gonzalez, J. Ramirez, F. J. Martinez-Murcia, F. Segovia, and J. M. Gorriz. "Analysis of I[123]-Ioflupane SPECT intensity iso-surfaces to assist the diagnosis of Parkinsonism." In 2018 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC). IEEE, 2018. http://dx.doi.org/10.1109/nssmic.2018.8824707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bhalchandra, Noopur A., R. Prashanth, Sumantra Dutta Roy, and Santosh Noronha. "Early detection of Parkinson's disease through shape based features from 123I-Ioflupane SPECT imaging." In 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI 2015). IEEE, 2015. http://dx.doi.org/10.1109/isbi.2015.7164031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Faro, A., D. Giordano, C. Pino, C. Spampinato, and A. Di Stefano. "3D Striatum reconstruction of 123Ioflupane SPECT images for quantitative assessments on the dopaminergic neurotransmission system." In 2010 IEEE International Workshop on Medical Measurements and Applications (MeMeA). IEEE, 2010. http://dx.doi.org/10.1109/memea.2010.5480220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ioflupano' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography